Lemeur Y, Moesch C, Rince M, Aldigier JC, Lerouxrobert C
Potential nephrotoxicity of intravenous infusions of
naftidrofuryl oxalate
Nephrol Dial Transplant
(Sep) 10:1751-1755 1995
Naftidrofuryl oxalate (not available in the United States) is used to treat
arteriosclerosis obliterans in the form of an intravenous infusion. This
report describes ARF associated with hyperoxaluria in two patients treated
with this compound. In a subsequent study, administration of 800 mg/day for
10 days resulted in large increased in serum and urinary oxalate levels.
Crystalluria was noted. The authors suggest that extreme caution must be
used when giving naftidrofuryl oxalate intravenously to avoid renal damage.
(Daugirdas)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
ARF etiology :
Other drug-associated ARF